Start Submission Become a Reviewer

Reading: Real-world clinical outcomes of anticancer treatments and prognostic factors in patients wit...

Download

A- A+
Alt. Display

Cohort Study

Real-world clinical outcomes of anticancer treatments and prognostic factors in patients with advanced melanoma in China

Authors:

Chuanliang Cui,

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, CN
About Chuanliang

MD

X close

Xieqiao Yan,

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, CN
About Xieqiao

MD

X close

Ben Li,

Department of Medical Oncology, MSD China, Beijing, CN
About Ben

MD

X close

Lu Si,

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, CN
About Lu

MD

X close

Chi Zhihong,

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, CN
About Chi

MD

X close

Xinan Sheng,

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, CN
About Xinan

MD

X close

Bin Lian,

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, CN
About Bin

MD

X close

Xuan Wang,

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, CN
About Xuan

MD

X close

Lili Mao,

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, CN
About Lili

MD

X close

Bixia Tang,

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, CN
About Bixia

MD

X close

Li Zhou,

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, CN
About Li

MD

X close

Xue Bai,

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, CN
About Xue

MD

X close

Siming Li,

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, CN
About Siming

MD

X close

Jun Guo

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, 52# Fucheng Road, Haidian District, Beijing 100142, CN
About Jun

MD

X close

Abstract

Purpose: China has much lower 5-year survival rates among melanoma patients than Western countries. This retrospective study describes real-world clinical outcomes and prognostic factors in locally advanced/metastatic melanoma in China.

Materials and methods: Adults patients with unresectable stage III or IV melanoma treated between January 1, 2014 and December 31, 2015, at the Beijing Cancer Hospital were eligible (data cutoff: December 31, 2017). The Kaplan-Meier method and Log-Rank test were used to estimate the median value of time-to-event outcomes. A Cox proportional hazards model was simulated to evaluate associations of patients’ characteristics with survival.

Results: Overall, there were 221 and 116 Chinese locally advanced and/or metastatic melanoma patients were enrolled in the first line (1L) and the second line (2L) treatments, respectively. The real-world objective response rate was <10% (1L: 6.3%; 2L: 3.4%); median progression-free survival was under 4 months (1L: 3.5; 2L: 2.3); median overall survival (OS) was <1 year (1L: 10.5; 2L: 7.5) with a low 12-month OS rate (43.5% for 1L, 30.5% for 2L). Based on univariate analyses, those with Eastern Cooperative Oncology Group (ECOG) Performance Status = 2 (vs. ECOG=0) in 1L, and 2L treatment (vs. 1L treatment) or ECOG =2 (vs. ECOG=1) among 1L/2L were associated with statistically significantly worse outcomes.

Conclusion: The current clinical outcomes in advanced melanoma patients in China are poor. High ECOG performance score independently increase risk of death both from 1L and 2L treatments, suggesting a high unmet medical need for immunotherapy in advanced melanoma.

How to Cite: Cui C, Yan X, Li B, Si L, Zhihong C, Sheng X, et al.. Real-world clinical outcomes of anticancer treatments and prognostic factors in patients with advanced melanoma in China. International Journal of Surgery: Oncology. 2020;5(5):e97. DOI: http://doi.org/10.1097/IJ9.0000000000000097
2
Views
Published on 09 Nov 2020.
Peer Reviewed

Downloads

  • PDF (EN)